Previous 10 | Next 10 |
2024-04-13 10:52:04 ET More on AbbVie, Amgen, etc. AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut GLP-1s benefit Park...
2024-04-11 15:23:48 ET Summary Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications. Povetacicept has shown promising results in reducing protei...
2024-04-10 02:32:14 ET Summary Rose's Income Garden (RIG) portfolio consists of 83 stocks from all 11 sectors, prioritizing income from defensive quality investment-grade common stock. The portfolio includes defensive stocks from sectors such as Consumer Staples, Healthcare, Commu...
2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...
2024-04-06 08:45:00 ET The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average...
2024-04-05 13:51:53 ET Summary As the retirement crisis looms, urgent action is key. The financial industry's failure to address rising retirement costs exacerbates the situation. Investing in dividend-growth stocks emerges as a crucial strategy. Realty Income, NextEra Energy, Pep...
2024-04-03 12:30:02 ET UBS analyst issues BUY recommendation for AMGN on April 3, 2024 11:00AM ET. The previous analyst recommendation was Buy. AMGN was trading at $275.52 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst re...
2024-04-03 11:28:49 ET Summary "The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.”–Dow Jones & Co. The highest-...
2024-04-02 03:42:59 ET Summary Successful retirement planning starts many years prior, especially amidst high inflation and skyrocketing home prices. Reaching retirement with enough money saved up, to live comfortably is only a part of the equation. Each individual has differe...
2024-04-01 06:08:19 ET Summary Cytokinetics' stock has seen much buyout speculation in recent months, with companies like Eli Lilly, Novartis, Johnson & Johnson, Amgen, and AstraZeneca being potential suitors. The company's Phase 3 study for aficamten, a treatment for heart di...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares are racing higher Wednesday. The company said it will report first-quarter results and provide an in...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 PR Newswire Findings From Tezspire ® (tezepelumab-ekko) Phase 2a COURSE COPD Study Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma New TAVNEOS ...
Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc&...